Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting
September 25 2017 - 8:00AM
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical studies evaluating its novel
echinocandin antifungal CD101 will be presented at two upcoming
infectious disease meetings. CD101 abstracts have been accepted for
presentation at both IDWeek 2017 in San Diego from October 4-8 and
at the 8th Trends in Medical Mycology (TIMM) meeting in Belgrade,
Serbia from October 6-9.
A total of six presentations will highlight the
unique attributes of CD101, Cidara’s lead antifungal drug candidate
and the only long-acting antifungal in the echinocandin class.
Specifically, data to be presented will showcase the potential
advantages of CD101, which has exhibited the following
characteristics: in vivo activity against emerging resistant
organisms; high target-attainment and exposure to treat less
susceptible pathogens; superior tissue penetration compared to
micafungin; and biofilm activity.
“These presentations reflect our comprehensive
program to build the foundation of a superior antifungal profile
for CD101,” said Jeffrey Stein, Ph.D., president and chief
executive officer of Cidara. “We are excited to share these
findings with medical professionals to reinforce our commitment to
provide new options for patients with deadly invasive fungal
infections.”
Details of the Cidara IDWeek and TIMM presentations
are as follows:
IDWeek 2017 Presentations
Friday, October 6: Poster Abstract Session
– Preclinical study with new antibiotics and antifungals (12:30
p.m. – 2:00 p.m. PT, San Diego Convention Center,
Poster Hall CD)
- 1518: Evaluation of the Efficacy of CD101, a Novel
Echinocandin, in the Treatment of Candida auris Infection Using a
Murine Model of Disseminated Candidiasis; C. Hager, et. al.
- 1528: In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target
Characterization of the Novel, Long Acting Echinocandin CD101
against C. albicans and C. glabrata in the
Neutropenic Murine Disseminated Candidiasis Model; A. J. Lepak, et.
al.
- 1533: Unraveling Drug Penetration of Echinocandin Antifungals
at the Site of Infection in an Intra-Abdominal Abscess Model; Y.
Zhao, et. al.
2017 TIMM Presentations
Saturday, October 7: Poster Session (11:00
a.m. – 12:00 p.m. CEST, Sava Centre Congress Center, Poster
Area)
- P057: Evaluate the Ability of CD101 to Prevent and Treat
Candida albicans Biofilms and Explore its Temporal Effect by Time
Lapse Photography; J. Chandra, et. al.
- P349: PK/PD Target Characterization of the Novel Echinocandin
CD101 Against Candida spp. in a Neutropenic Mouse Model of
Disseminated Candidiasis; A. J. Lepak, et. al.
Sunday, October 8: Session S15: New
antifungal drugs in the pipeline (2:15 p.m. – 4:00 p.m. CEST, Sava
Centre Congress Center)
- S15.2 (2:27 p.m.): CD101; T. Sandison
Copies of these posters and presentations will be
available on the Cidara website following the meetings:
http://www.Cidara.com/
About Fungal Infections
Approximately 97,000 Americans die from
hospital-related fungal infections each year and 90 percent of
these infections are caused by two common fungi, Candida and
Aspergillus. The emergence of a new and virulent fungal pathogen
called Candida auris (C. auris) is also an emerging public health
threat due to its resistance to existing antifungal agents. As of
July 2017, the Centers for Disease Control and Prevention (CDC)
reports that C. auris has been identified in more than 200 patients
in the United States. Cidara is currently evaluating CD101 in C.
auris, in addition to multiple other invasive fungal
infections.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company
focused on developing new anti-infectives that have the potential
to transform the standard of care and save or improve patients’
lives. The company is currently advancing its novel echinocandin
antifungal, CD101 IV, through Phase 2 and developing CD201, its
bispecific antibiotic immunotherapy, for the treatment of
multi-drug resistant Gram-negative bacterial infections. CD101 IV
has improved pharmacokinetics compared to existing echinocandins
and has the potential for expanded utility across patient settings.
CD101 IV is the only once-weekly product candidate in development
for the treatment and prevention of life-threatening invasive
fungal infections. CD201 is the first drug candidate selected from
Cidara’s novel Cloudbreak™ platform, the first immunotherapy
discovery platform designed specifically to create compounds that
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara has received a grant for up to
$6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria
Accelerator) to advance the development of CD201. Cidara is
headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding the potential advantages, effectiveness,
safety, and other attributes of CD101 and other potential product
candidates, including the potential for these compounds to
successfully treat or prevent infections, including those caused by
resistant pathogens, and potentially transform the way infectious
diseases are treated, and the potential for the Cloudbreak platform
to result in future drug candidates. Risks that contribute to the
uncertain nature of the forward-looking statements include: the
success and timing of Cidara’s preclinical studies and clinical
trials; regulatory developments in the United States and foreign
countries; changes in Cidara’s plans to develop and commercialize
its product candidates; Cidara’s ability to obtain additional
financing; Cidara’s ability to obtain and maintain intellectual
property protection for its product candidates; and the loss of key
scientific or management personnel. These and other risks and
uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
INVESTOR CONTACT:Robert H.
UhlWestwicke Partners, LLCManaging Director(858)
356-5932robert.uhl@westwicke.com
MEDIA CONTACT:Christy Curran Sam
Brown Inc.615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024